Osteopenia treatment centers on lifestyle measures for most people and reserves medication for those at genuinely elevated fracture risk. The condition sits between normal bone density and osteoporosis, and the fact that it is a middle zone rather than a clear-cut disease shapes every treatment decision. For the majority of people with osteopenia, weight-bearing exercise, adequate calcium and vitamin D, and fall prevention do the heavy lifting. Medication enters the picture only when fracture risk calculators flag someone as high-risk, and the cost-effectiveness of blanket drug treatment for osteopenia remains contested.
Not Everyone With Osteopenia Needs Medication
The most important thing to understand about osteopenia treatment is that a low-ish bone density reading on a scan does not automatically mean you need a prescription. Most osteoporotic fractures actually occur in people whose bone density falls in the osteopenia range rather than the osteoporosis range, simply because far more people have osteopenia than osteoporosis. But that population-level statistic does not mean your personal risk is high enough to justify drugs.
A key review on treating osteopenia noted that the number of osteopenic patients you would need to treat to prevent one fracture is much higher than in osteoporosis patients, sometimes exceeding 100, compared with roughly 10 to 20 for someone with established osteoporosis and a prior fracture.1PubMed Central. Treatment of osteopenia That means treating osteopenia with drugs on the basis of bone density alone is generally not advisable. Guidelines recommend considering medication only when osteopenia is paired with additional risk factors, such as a prior low-energy fracture or a high score on the FRAX fracture risk assessment tool. Specifically, pharmacological treatment is typically considered when someone has a ten-year hip fracture risk of at least 3% or a ten-year risk of a major osteoporotic fracture of at least 20%.2PubMed Central. The assessment of fracture risk
Cost-effectiveness analyses have reinforced this conservative approach. A study modeling different screening and treatment strategies for postmenopausal women found no compelling evidence that treating women with osteopenia and no history of fracture is cost-effective.3PubMed Central. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women So if your bone density scan comes back showing osteopenia and your doctor says “let’s watch and wait,” that is not neglect. It is evidence-based medicine.
Exercise That Actually Builds Bone
If there is one treatment that virtually every expert agrees on for osteopenia, it is resistance exercise. Bones respond to mechanical stress that exceeds what they encounter during everyday activities. When muscles pull on bone during weighted movements, they trigger a remodeling response that deposits new bone tissue.4PubMed Central. Effects of Resistance Exercise on Bone Health Walking is fine for general health, but it usually does not impose enough load on the skeleton to meaningfully shift bone density.
A meta-analysis of high-load resistance training in people with osteoporosis and osteopenia found significant increases in bone mineral density at the lumbar spine, femoral neck, and total hip.5PubMed. Impact of high-load resistance training on bone mineral density in osteoporosis and osteopenia: a meta-analysis Intensity matters here. A trial comparing high-intensity versus low-intensity resistance training in postmenopausal women with osteopenia found that the high-intensity group gained significantly more bone mineral density, though even the low-intensity group outperformed the control group that did nothing.6PubMed Central. High versus Low-Intensity Resistance Training on Bone Mineral Density and Content Acquisition by Postmenopausal Women with Osteopenia: A Randomized Controlled Trial The takeaway is straightforward: heavier loads produce better bone results, but lighter loads still beat inactivity.
One caveat involves whole-body vibration platforms, which have been marketed as a bone-building alternative. A randomized trial in postmenopausal women with osteopenia found that neither vibration training nor resistance training in that particular protocol significantly changed bone density scores compared to the control group over the study period, though all three groups at least maintained their bone density.7PubMed Central. Effects of whole body vibration in postmenopausal osteopenic women on bone mineral density, muscle strength, postural control and quality of life: the T-bone randomized trial If you are choosing between a vibration platform and a barbell, the evidence favors the barbell.
Calcium, Vitamin D, and Diet
Calcium and vitamin D form the nutritional foundation of every osteopenia management plan. They are not optional add-ons. Even when someone starts bone-specific medication, continued calcium and vitamin D intake is recommended for optimal fracture risk reduction.8PubMed Central. The use of calcium and vitamin D in the management of osteoporosis Getting enough from food is ideal. Dairy, fortified plant milks, canned fish with bones, and leafy greens supply calcium. Vitamin D comes from sunlight exposure, fatty fish, and fortified foods, though many people in northern latitudes or with indoor lifestyles end up supplementing.
Beyond individual nutrients, overall dietary patterns seem to matter. Research on the Mediterranean diet has shown that adherence to this eating pattern benefits bone mineral density and muscle mass.9PubMed Central. The Influence of the Mediterranean Dietary Pattern on Osteoporosis and Sarcopenia A secondary analysis of a randomized clinical trial found that a Mediterranean diet intervention combined with physical activity led to a modest but real increase in lumbar spine bone density over three years compared to a control group, with the protective effect particularly pronounced in women.10JAMA Network Open. Mediterranean Diet, Physical Activity, and Bone Health in Older Adults: A Secondary Analysis of a Randomized Clinical Trial The Mediterranean diet is rich in olive oil, fish, vegetables, nuts, and whole grains, and it brings anti-inflammatory compounds and a broad spectrum of minerals that collectively support bone remodeling.
When Medication Is Warranted
For the subset of people with osteopenia whose fracture risk is genuinely high, several drug classes have evidence behind them. Bisphosphonates are the most studied. These drugs slow bone breakdown by reducing the activity of the cells that dissolve old bone tissue, which shifts the balance toward net bone gain. A systematic review focused specifically on bisphosphonate use in osteopenia confirmed their role in both reducing fracture risk and increasing bone mineral density in this population.11PubMed Central. Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review
The strongest single trial in this space involved over 2,000 older women with osteopenia who received either zoledronate (an intravenous bisphosphonate given once every 18 months) or placebo. The zoledronate group had about a 37% lower rate of fragility fractures overall. The number needed to treat was 15, meaning you would treat 15 women with zoledronate to prevent one fracture. Vertebral fractures dropped by about half, and the drug also reduced height loss.12PubMed. Fracture Prevention with Zoledronate in Older Women with Osteopenia That number needed to treat of 15 is much better than the general figure of over 100 sometimes cited for treating all osteopenic patients indiscriminately, which highlights why patient selection matters so much. The women in this trial were older (average age 71) and were selected partly because their risk profile was elevated.
Evidence from trials confirms that both oral and intravenous bisphosphonates can cost-effectively reduce fractures in older women with osteopenia when appropriately targeted.13PubMed. Osteopenia: a key target for fracture prevention The key phrase is “appropriately targeted.” Prescribing these drugs to every 55-year-old with a T-score of −1.2 would be a different calculation entirely.
SERMs and Other Options
Selective estrogen receptor modulators, or SERMs, offer an alternative for postmenopausal women. Raloxifene is the best-known drug in this class. It mimics some of estrogen’s bone-protective effects without stimulating breast or uterine tissue the way estrogen does. In women with osteoporosis, raloxifene reduces vertebral fractures by roughly 30% to 50%, although it has not been shown to reduce hip fractures.14PubMed Central. Raloxifene for older women: a review of the literature That distinction is worth noting if hip fracture is your primary concern.
A study looking at SERMs specifically in postmenopausal women with osteopenia found improvements in both spine and hip bone mineral density, and none of the treated patients experienced fractures during the follow-up period.15PubMed Central. The Efficacy of Selective Estrogen Receptor Modulators Monotherapies in Postmenopausal Women with Osteopenia SERMs are sometimes positioned as a preventive treatment for women who are not yet osteoporotic but are losing bone at an accelerating pace. They are not as commonly prescribed as bisphosphonates but remain a legitimate option, especially for women who also want the reduced breast cancer risk that raloxifene provides.
The Controversy Around Treating Osteopenia With Drugs
There is genuine disagreement in the medical community about how aggressively to medicate osteopenia. On one side, the argument is practical: most fractures come from the osteopenic population, so treating those people could prevent more total fractures than treating only the smaller group with osteoporosis. On the other side, the math of absolute risk reduction is unfavorable. A large trial found that the number needed to treat to prevent one fracture was about three and a half times higher in women with osteopenia than in those with osteoporosis, even though the relative risk reduction looked similar on paper.16PubMed Central. Non-medicalization of medical science: Rationalization for future
Some researchers have argued that osteopenia without risk factors is best described as a radiological finding rather than a disease requiring medication. It requires periodic monitoring, lifestyle measures, and repeat fracture risk assessment, but not necessarily drugs. Alendronate, one of the most common oral bisphosphonates, was not associated with a significant reduction in vertebral fracture risk among women with T-scores between −1.6 and −2.5 in the fracture intervention trial, according to that same review.17PubMed Central. Non-medicalization of medical science: Rationalization for future The long duration of treatment, undefined endpoints, and potential side effects all feed into the argument for restraint.
Risks of Long-Term Bisphosphonate Use
The side effect that gets the most attention is atypical femoral fracture. These are unusual breaks in the thighbone that occur with minimal or no trauma, often in the middle of the bone shaft rather than at the hip. They differ from typical osteoporotic fractures in location, pattern, and mechanism. The proposed explanation is that bisphosphonates suppress bone turnover so aggressively that the bone loses its ability to repair microdamage, eventually leading to a stress fracture.18PubMed Central. Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention
Adverse event reporting data confirms that several anti-resorptive drugs, including alendronate, risedronate, ibandronate, pamidronate, and denosumab, are associated with elevated reports of atypical femoral fractures.19PubMed Central. Current concepts in the management of bisphosphonate associated atypical femoral fractures The relative risk is real but the absolute risk is low compared to the number of osteoporotic fractures prevented. This is why many guidelines recommend bisphosphonate “holidays” after three to five years of use, where the drug is paused and bone health is reassessed. For people with osteopenia rather than full osteoporosis, the risk-benefit equation tilts even more cautiously, because the fracture risk being prevented is already lower to begin with.
Fall Prevention Matters as Much as Bone Density
You can have strong bones and still break them if you fall badly enough. Conversely, someone with osteopenia who never falls may never fracture. This is why fall prevention is increasingly seen as a core part of osteopenia management rather than an afterthought. A review of 50 randomized controlled trials found that resistance and impact training consistently improved body strength and balance while reducing fall rates, even in people with osteoporosis and osteopenia.20PubMed Central. Position Statement: Exercise Guidelines for Osteoporosis Management and Fall Prevention in Osteoporosis Patients
A systematic review focused specifically on people with low bone density found that exercise interventions featuring balance training reduced falls or fall-related fractures and improved balance in most of the studies examined.21PubMed. Exercise interventions to reduce fall-related fractures and their risk factors in individuals with low bone density: a systematic review of randomized controlled trials Targeted exercise programs in osteopenic women have also shown significant improvements in both balance and strength.22PubMed. Positive effects of exercise on falls and fracture risk in osteopenic women The practical upshot: if you have osteopenia, investing in balance and leg strength may prevent more fractures than fixating on your T-score. Simple changes like removing tripping hazards at home, improving lighting, reviewing medications that cause dizziness, and wearing supportive shoes all contribute.
Medications That Cause Bone Loss
If your osteopenia has a treatable cause, addressing that cause becomes the most direct form of treatment. Several common medications accelerate bone loss. Aromatase inhibitors, widely prescribed to postmenopausal women after breast cancer, are associated with significantly more osteoporotic fractures and greater bone mineral loss.23PubMed Central. Aromatase inhibitors and bone loss Long-term corticosteroids, certain anti-seizure medications, proton pump inhibitors used for reflux, and some cancer therapies also contribute. If you are taking one of these drugs and your bone density is dropping, your doctor may consider adding a bone-protective medication alongside the offending drug, or switching to an alternative with fewer skeletal side effects.
Other secondary causes include untreated thyroid or parathyroid disorders, celiac disease or other conditions that impair nutrient absorption, heavy alcohol use, and smoking. A workup for secondary causes is especially warranted in anyone who develops osteopenia at a younger age or loses bone faster than expected.
Beyond Bone Density Scans
Standard bone density scans (DXA) measure how much mineral is packed into a given area of bone, but they do not capture the internal architecture. Two people with identical T-scores can have very different fracture risks depending on the structural quality of their bone. This is where the trabecular bone score, or TBS, comes in. TBS is an indirect measure of bone microarchitecture derived from the same DXA scan image. A low TBS indicates degraded internal bone structure and predicts fractures partly independently of bone mineral density.24PubMed Central. Update on trabecular bone score
The OFELY study found that over a third of fractures occurred in women in the lowest quartile of TBS, regardless of their bone density reading.25PubMed. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study TBS and standard bone mineral density are only moderately correlated, meaning they capture different aspects of bone health.26PubMed. Bone mineral density (BMD) and vertebral trabecular bone score (TBS) for the identification of elderly women at high risk for fracture: the SEMOF cohort study TBS is now incorporated into updated versions of the FRAX calculator, which means it can push someone’s estimated fracture risk higher or lower than the standard DXA T-score alone would suggest. If you have osteopenia and your doctor is on the fence about medication, TBS can help tip the decision one way or the other.
Building the Bone Bank Early
Peak bone mass, the highest bone density you will ever achieve, is reached somewhere between your late teens and late twenties. After that, bone density gradually declines for the rest of your life. Research has shown a significant positive correlation between peak bone mass and the bone density you carry into later decades.27PubMed Central. Peak bone mass and patterns of change in total bone mineral density and bone mineral contents from childhood into young adulthood The idea is sometimes framed as a “bone bank”: the more you deposit early, the more you can afford to lose later without dipping into the osteopenia range.
Some researchers have argued that the ultimate target population for osteoporosis prevention may be young people rather than the elderly, because building a higher peak through exercise, nutrition, and healthy habits during adolescence could provide protection that lasts a lifetime.28PubMed Central. Is osteoporosis a pediatric disease? Peak bone mass attainment in the adolescent female. This framing does not help if you are already 60 and reading about osteopenia treatment, but it is worth knowing for anyone raising teenagers or young adults. Encouraging weight-bearing sports, adequate dairy or calcium intake, and enough vitamin D during those years is one of the most effective long-term strategies against osteopenia that exists.
The Gut Microbiome and Bone
An emerging area of research links the bacteria living in your gut to bone health. People with lower bone mineral density tend to show altered gut microbiota at multiple levels of classification.29Food Science and Human Wellness. Targeting gut microbiota in osteoporosis: impact of the microbial-based functional food ingredients The proposed mechanisms run through several pathways: gut bacteria influence how well you absorb minerals like calcium from food, they affect the integrity of the intestinal lining, and they interact with both the immune system and the endocrine system in ways that modulate bone turnover.
Animal studies have demonstrated that certain gut microbes can increase bone mass by inhibiting the cells that break down bone and promoting the cells that build it.30PubMed Central. Gut Microbiome and Osteoporosis Whether probiotics or dietary interventions that reshape the gut microbiome will someday become a standard part of osteopenia treatment is still an open question. The research is mostly preclinical or observational at this point. But it helps explain why dietary patterns like the Mediterranean diet, which are rich in fiber and fermented foods that feed beneficial gut bacteria, tend to be associated with better bone outcomes. If nothing else, it is another reason to eat a varied diet heavy on vegetables, whole grains, and fermented foods rather than relying solely on a calcium pill.